Special Issue "Immune Modulation to SARS-CoV-2 Vaccination and Infection"

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Molecular Microbiology and Immunology".

Deadline for manuscript submissions: 15 October 2023 | Viewed by 2630

Special Issue Editor

Department of Medicine and Surgery, LUM University Giuseppe Degennaro, Casamassima, BA, Italy
Interests: immune response to SARS-CoV-2; murine models of infection with Salmonella and Streptococcus pneumoniae; vaccination in mice; T-cell priming; mucosal vaccination; memory cells

Special Issue Information

Dear Colleagues,

SARS-CoV-2 infected more than 6 million people worldwide, with different clinical outcomes. Continuous new challenges are emerging for the rapid mutations in the viral genome. Scientists are working hard to search for appropriate advanced therapies to treat COVID-19 and investigate new safe and effective vaccines capable of efficiently prevent the infection.

Until now, different vaccines have been licensed sooner and others are under investigation. Although the vaccination strongly reduced severe illness, and new findings and research continuously expand our knowledge about COVID-19 and SARS-CoV-2 infection, it is critical to investigate the type and the timing of immune response generated using licensed and/or new experimental vaccines, and new efficient approaches based on different delivery systems or route of vaccination.

The Special Issue “Immune Modulation to SARS-CoV-2 Vaccination and Infection” aims to assemble a collection of original research articles and reviews that explore, in pre-clinical and clinical studies, the innate and adaptive immune response elicited by infection with SARS-CoV-2, or induced by different type of vaccines against SARS-CoV-2. Research works evaluating the modulation of the immune response to vaccination and/or infection, studying the type, the magnitude, the quality, and the persistence of the immune response, are welcomed.

Dr. Fabio Fiorino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • SARS-CoV-2
  • infection
  • immune response
  • antibody response
  • memory cells
  • vaccine
  • vaccine delivery
  • route of immunization
  • immune persistence

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity
Microorganisms 2023, 11(2), 452; https://doi.org/10.3390/microorganisms11020452 - 10 Feb 2023
Cited by 6 | Viewed by 2290
Abstract
Gut microbiota is increasingly recognized to play a pivotal role in various human physiological functions and diseases. Amidst the COVID-19 pandemic, research has suggested that dysbiosis of the gut microbiota is also involved in the development and severity of COVID-19 symptoms by regulating [...] Read more.
Gut microbiota is increasingly recognized to play a pivotal role in various human physiological functions and diseases. Amidst the COVID-19 pandemic, research has suggested that dysbiosis of the gut microbiota is also involved in the development and severity of COVID-19 symptoms by regulating SARS-CoV-2 entry and modulating inflammation. Previous studies have also suggested that gut microbiota and their metabolites could have immunomodulatory effects on vaccine immunogenicity, including influenza vaccines and oral rotavirus vaccines. In light of these observations, it is possible that gut microbiota plays a role in influencing the immune responses to COVID-19 vaccinations via similar mechanisms including effects of lipopolysaccharides, flagellin, peptidoglycan, and short-chain fatty acids. In this review, we give an overview of the current understanding on the role of the gut microbiota in COVID-19 manifestations and vaccine immunogenicity. We then discuss the limitations of currently published studies on the associations between gut microbiota and COVID-19 vaccine outcomes. Future research directions shall be focused on the development of microbiota-based interventions on improving immune response to SARS-CoV-2 infection and vaccinations. Full article
(This article belongs to the Special Issue Immune Modulation to SARS-CoV-2 Vaccination and Infection)
Show Figures

Figure 1

Back to TopTop